Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All?

33Citations
Citations of this article
76Readers
Mendeley users who have this article in their library.

Abstract

The last 2 decades have seen a surge in the number of amyotrophic lateral sclerosis (ALS) clinical trials with the hope of finding successful treatments. Clinical trialists aim to repurpose existing drugs and test novel compounds to target potential ALS disease pathophysiology. Recent technological advancements have led to the discovery of new causative genetic agents and modes of delivering potential therapy, calling for increasingly sophisticated trial design. The standard ALS clinical trial design may be modified depending on study needs: type of therapy; route of therapy delivery; phase of therapy development; applicable subpopulation; market availability of therapy; and utility of telemedicine. Novel biomarkers of diagnostic, predictive, prognostic, and pharmacodynamic value are undergoing development and validation for use in clinical trials. Design modifications build on the traditional clinical trial design and may be employed in either the learning or confirming trial phase. Novel designs aim to minimize patient risk, study duration, and sample size, while improving efficiency and promoting statistical power to herald an exciting era for clinical research in ALS.

References Powered by Scopus

Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework

5347Citations
N/AReaders
Get full text

Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons

1687Citations
N/AReaders
Get full text

The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS

1016Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Amyotrophic lateral sclerosis

1252Citations
N/AReaders
Get full text

Development of multifunctional molecules as potential therapeutic candidates for Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis in the last decade

447Citations
N/AReaders
Get full text

Animal models of neurodegenerative diseases

386Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Nicholson, K. A., Cudkowicz, M. E., & Berry, J. D. (2015, April 1). Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All? Neurotherapeutics. Springer New York LLC. https://doi.org/10.1007/s13311-015-0341-2

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 24

60%

Researcher 8

20%

Professor / Associate Prof. 5

13%

Lecturer / Post doc 3

8%

Readers' Discipline

Tooltip

Medicine and Dentistry 21

57%

Agricultural and Biological Sciences 7

19%

Neuroscience 5

14%

Biochemistry, Genetics and Molecular Bi... 4

11%

Save time finding and organizing research with Mendeley

Sign up for free